Roanna Ruiz has given her Buy rating due to a combination of factors that highlight Lexicon Pharmaceuticals’ strategic advancements and potential for value growth. One significant reason is the ...

Viatris is ponying up $25 million upfront to obtain the rights to sell Lexicon Pharmaceuticals’ SGLT1/SGLT2 heart med sotagliflozin, known commercially as Inpefa, in all global markets beyond ...

(Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets ...